How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Biocatalysis Biocatalyst Market
- By Biocatalyst Type: Enzymes, Whole Cells, Immobilized Biocatalysts, Recombinant Biocatalysts
- By Enzyme Class: Oxidoreductases, Hydrolases, Lyases, Isomerases, Ligases
- By Application: Pharmaceuticals, Food and Beverages, Biofuels, Agriculture, Fine Chemicals
- By Formulation: Free Enzymes, Immobilized Enzymes, Enzyme Blends
- By Source Organism: Microbial, Plant-derived, Animal-derived, Recombinant Microorganisms
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Enzymes leads By Biocatalyst Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Biocatalysis Biocatalyst Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Biocatalyst Type 4
Enzyme Class 5
Application 5
Formulation 3
Source Organism 4
Companies profiled
Novozymes A/S
Codexis Inc.
DSM (Royal DSM N.V.)
DuPont (including DuPont Nutrition & Biosciences)
BASF SE
Evonik Industries AG
Chr. Hansen Holding A/S
Amano Enzyme Inc.
Advanced Enzyme Technologies Ltd.
Creative Enzymes
Enzyme Development Corporation
Megazyme
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novozymes A/S
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Codexis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →DSM (Royal DSM N.V.)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →DuPont (including DuPont Nutrition & Biosciences)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Evonik Industries AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Chr. Hansen Holding A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Amano Enzyme Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Advanced Enzyme Technologies Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Creative Enzymes
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Enzyme Development Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Megazyme
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AB Enzymes GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Kerry Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Biocatalysts Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,900M by 2033 · 10.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Enzymes54.8
- Whole Cells15.2
- Immobilized Biocatalysts20.0
- Recombinant Biocatalysts10.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,019M → $2,469M · 11.7%
Europe$710.3M → $1,755M · 12.0%
Asia Pacific$648.5M → $1,475M · 10.8%
Latin America$401.5M → $841.3M · 9.7%
Middle East and Africa$308.8M → $747.0M · 11.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.522026
10.542027
10.562028
10.562029
10.582030
10.592031
10.592032
10.612033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novozymes A/S13.3
- Codexis Inc.24.7
- DSM (Royal DSM N.V.)7.6
- DuPont (including DuPont Nutrition & Biosciences)11.6
- BASF SE4.8
- Evonik Industries AG10.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Biocatalyst Type13.8%
Enzyme Class15.1%
Application25.4%
Formulation23.6%
Source Organism22.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.9
- Europe24.1
- Asia Pacific20.2
- Latin America11.5
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novozymes A/S | 97 | 97 | 89 | 88 | 80 | 80 | 89 |
| Codexis Inc. | 88 | 83 | 88 | 88 | 85 | 70 | 84 |
| DSM (Royal DSM N.V.) | 83 | 64 | 64 | 85 | 87 | 87 | 78 |
| DuPont (including DuPont Nutrition & Biosciences) | 60 | 70 | 58 | 78 | 78 | 60 | 67 |
| BASF SE | 65 | 62 | 62 | 74 | 68 | 64 | 66 |
| Evonik Industries AG | 49 | 49 | 50 | 50 | 56 | 55 | 52 |
| Chr. Hansen Holding A/S | 60 | 60 | 46 | 54 | 42 | 54 | 53 |
| Amano Enzyme Inc. | 47 | 59 | 59 | 37 | 58 | 42 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novozymes A/S
- Codexis Inc.
- DSM (Royal DSM N.V.)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novozymes A/S | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Codexis Inc. | ✓ | ✓ | ◐ | ✓ | ◐ | − |
| DSM (Royal DSM N.V.) | ◐ | − | − | ✓ | ✓ | ◐ |
| DuPont (including DuPont Nutrition & Biosciences) | − | ✓ | ◐ | ◐ | ◐ | ◐ |
| BASF SE | − | − | ◐ | ◐ | ✓ | ✓ |
| Evonik Industries AG | − | ◐ | − | ◐ | ◐ | ◐ |
| Chr. Hansen Holding A/S | − | − | − | − | − | ◐ |
| Amano Enzyme Inc. | ◐ | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novozymes A/S89
2Codexis Inc.84
3DSM (Royal DSM N.V.)78
4DuPont (including DuPont Nutrition & Biosciences)67
5BASF SE66
6Chr. Hansen Holding A/S53
7Evonik Industries AG52
8Amano Enzyme Inc.50
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Novozymes A/SCodexis Inc.DSM (Royal DSM N.V.)
Challenger1
Strong scale, closing on the leaders.
DuPont (including DuPont Nutrition & Biosciences)
Contender1
Focused players with pockets of strength.
BASF SE
Niche3
Specialists in a single segment or region.
Evonik Industries AGChr. Hansen Holding A/SAmano Enzyme Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Biocatalyst Type in North America, then scale across Biocatalysis Biocatalyst Market — a $573M beachhead inside a $9.39B market.
Beachhead (SOM)$573Mobtainable near-term
Serviceable (SAM)$3.50Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Enzymes
Best fit — highest urgency & budget in Biocatalyst Type.
Economic buyer81 fit
Whole Cells
Strong fit — clear ROI and a fast path to value.
End user66 fit
Immobilized Biocatalysts
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Biocatalyst Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Enzyme Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Biocatalyst Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biocatalysis Biocatalyst Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified22%
Evaluation14%
Closed-won7%
$16.2KCAC
$72KLTV
4.4:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Biocatalysis Biocatalyst Market is a durable-growth opportunity — $4.75B by 2033, compounding at 6.8%.
TAM · 2025$2.81Btoday
TAM · 2033$4.75Bforecast
CAGR6.8%2027–2033
Cumulative$33.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.75BTotal addressable market
SAM$1.92BServiceable available market
SOM$351MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.8% CAGR
Demand compounds through 2033, outpacing GDP across Biocatalyst Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Biocatalyst Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.75BLarge & growingTAM by 2033 at 6.8% CAGR
$1.92BServiceable nowreachable with today’s model
$351MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.70BBear4.4% CAGR
$4.75BBase6.8% CAGR
$6.08BBull9.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Enzyme Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Biocatalysis Biocatalyst Market — a $4.31B market by 2033. Plan: grow share from 8.4% to 17.1%.
Market size · 2033$4.31Btotal addressable
Market CAGR3.7%2027–2033
Target share17.1%from 8.4% today
Revenue ambition$737Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 17.1% | At risk |
| Revenue | $333M | $737M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.4% | 45.2% | On track |
| Customer retention | 84.5% | 95.2% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Biocatalyst Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Enzyme Class capability
A defensible second engine — invest in Enzyme Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Biocatalyst Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Enzyme Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $99M capacity & capability investment
- Greenlight bolt-on M&A in Enzyme Class
- Authorise North America expansion plan
- Fund R&D program for Biocatalyst Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Biocatalysis Biocatalyst Market conversation — a $4.26B market you can size, segment and defend in minutes.
Market size · 2033$4.26Btotal opportunity
Growth7.0%CAGR to 2033
Addressable buyers976+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Biocatalyst Type
Goal Grow share in Biocatalyst Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 2 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Novozymes A/SCodexis Inc.DSM (Royal DSM N.V.)DuPont (including DuPont Nutrition & Biosciences)BASF SEEvonik Industries AGChr. Hansen Holding A/SAmano Enzyme Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biocatalysis Biocatalyst Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biocatalysis Biocatalyst Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Gestodene Market
Gestodene Market is valued at USD 215 Million in 2025 and is expected to reach USD 262 Million …
$215M market · 2025 base year
View reportGestational Trophoblastic Disease Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportGestational Diabetes Treatment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportGermicidal Wipes Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportGermicidal UV Striplight Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportGermicidal Spray Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportGermicidal Mouthwash Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportGermicidal Light Bulbs Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportGerm Free Mice Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportSpunlace Nonwoven Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportDioctyl Sulfosuccinate Sodium Salt Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportSmart Sleep Tracker Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.